Table 1 Baseline characteristics and response in patients salvaged with venetoclax.
Baseline characteristic | Total n = 29 | Responders | Non responders | P value (Fisher’s exact test) |
|---|---|---|---|---|
Age | 58 years (20–72 years) | 58 years (20–64 years) | 57 years (25–72) | 0.08 |
Sex | Â | Â | Â | 0.2 |
Male | 14 (48%) | 7 (50%) | 7 (50%) | Â |
Female | 15 (52%) | 4 (27%) | 11 (73%) | Â |
AML type | Â | Â | Â | 0.8 |
De novo | 11 (38%) | 5 (45%) | 6 (55%) | Â |
Secondary* | 5 (17%) | 2 (40%) | 3 (60%) | Â |
t-AML | 3 (10%) | 1 (33%) | 2 (67%) | Â |
High-risk MDS | 10 (35%) | 3 (30%) | 7 (70%) | Â |
Cytogenetic risk group | Â | Â | Â | 0.7 |
Favorable (inv 16) | 1 (3%) | 0 | 1 (100%) | Â |
Intermediate | 10 (35%) | 4 (36%) | 7 (64%) | Â |
Adverse | 18 (62%) | 7 (39%) | 11 (61%) | Â |
TP53 deletion or mutation | Â | Â | Â | 0.7 |
Yes | 12 (41%) | 4 (33%) | 8 (67%) | Â |
No | 17 (59%) | 7 (41%) | 10 (59%) | Â |
Median no. of therapies prior to transplant | 2 (range 1–4) | 2 (range 1–4) | 2 (range 0–3) |  |
AML/MDS status at transplant | Â | Â | Â | 0.1 |
CR1 | 20 (69%) | 8 (47%) | 9 (53%) | Â |
CR2 | 5 (17%) | 3 (60%) | 2 (40%) | Â |
Persistent disease or MRD positive | 3 (11%) | 0 | 3 (100%) | Â |
Upfront transplant | 1 (3%) | 0 | 1 (100%) | Â |
Time to relapse post transplant | 9 months (range 2–37 months) | 15 (range 2–37 months) | 7.5 (range 2–35) | 0.4 |
Time to venetoclax initiation from transplant | 13 months (range 2–48) |  |  |  |
AML status at venetoclax initiation | Â | Â | Â | 0.8 |
Relapse 1 post transplant | 21 (72%) | 8 (38%) | 13 (62%) | Â |
Relapse 2 post transplant | 4 (14%) | 2 (50%) | 2 (50%) | Â |
Relapse 3 and/or refractory disease | 4 (14%) | 1 (25%) | 3 (75%) | Â |
Median no. of venetoclax cycles | 2 (range 1–8) |  |  |  |
Prior HMA exposure | Â | Â | Â | 0.4 |
Yes | 12 (41%) | 3 (25%) | 9 (75%) | Â |
No | 17 (59%) | 8 (47%) | 9 (53%) | Â |
